Related Experiment Video
Updated: Aug 10, 2026

11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 31, 2013
Multivariate analysis of progression in superficial bladder cancer
P Sánchez de la Muela1, D Rosell, L Agüera
1Department of Urology, University Hospital, Pamplona, Spain.
British Journal of Urology
|March 1, 1993
Summary
An increasing grade of anaplasia is a key predictor of tumor progression in superficial bladder cancer (SBC). This factor, along with tumor category, significantly impacts prognosis and the likelihood of cancer-related death.
Area of Science:
- Urology
- Oncology
- Pathology
Background:
- Superficial bladder cancer (SBC) encompasses Ta-T1 categories, with varying risks of recurrence and progression.
- Understanding prognostic factors is crucial for managing SBC and preventing adverse outcomes.
Purpose of the Study:
- To retrospectively analyze tumor progression and identify prognostic factors in patients with superficial bladder cancer (SBC).
- To evaluate the predictive value of increasing grade of anaplasia for tumor progression and survival.
Main Methods:
- Retrospective analysis of 217 patients with superficial bladder cancer (SBC) (Ta-T1).
- Assessment of tumor recurrence, grade of anaplasia, tumor category, and survival rates.
- Multivariate statistical analysis to determine significant prognostic factors.
Main Results:
- 46% of patients experienced recurrences; 13% showed increasing grades of anaplasia; 12% had tumor category progression.
- Increasing grade of anaplasia predicted tumor progression with 91% accuracy.
- Tumor category and increasing grade of anaplasia were significant prognostic indicators.
- Patients with increasing grade of anaplasia and progression had higher rates of muscle invasion, metastasis, and cancer-related death.
Conclusions:
- Increasing grade of anaplasia is a critical factor influencing prognosis in superficial bladder cancer (SBC).
- It identifies patients at high risk for tumor progression and cancer-related mortality, particularly in T1 bladder cancer.
- Early identification of these risk factors can guide treatment strategies and improve patient outcomes.

